table of content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2023-2028)
1.4.2 East Asia Market States and Outlook (2023-2028)
1.4.3 Europe Market States and Outlook (2023-2028)
1.4.4 South Asia Market States and Outlook (2023-2028)
1.4.5 Southeast Asia Market States and Outlook (2023-2028)
1.4.6 Middle East Market States and Outlook (2023-2028)
1.4.7 Africa Market States and Outlook (2023-2028)
1.4.8 Oceania Market States and Outlook (2023-2028)
1.4.9 South America Market States and Outlook (2023-2028)
1.5 Global Anti-Parkinson Drugs Market Size Analysis from 2023 to 2028
1.5.1 Global Anti-Parkinson Drugs Market Size Analysis from 2023 to 2028 by Consumption Volume
1.5.2 Global Anti-Parkinson Drugs Market Size Analysis from 2023 to 2028 by Value
1.5.3 Global Anti-Parkinson Drugs Price Trends Analysis from 2023 to 2028
1.6 COVID-19 Outbreak: Anti-Parkinson Drugs Industry Impact
Chapter 2 Global Anti-Parkinson Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Anti-Parkinson Drugs (Volume and Value) by Type
2.1.1 Global Anti-Parkinson Drugs Consumption and Market Share by Type (2017-2022)
2.1.2 Global Anti-Parkinson Drugs Revenue and Market Share by Type (2017-2022)
2.2 Global Anti-Parkinson Drugs (Volume and Value) by Application
2.2.1 Global Anti-Parkinson Drugs Consumption and Market Share by Application (2017-2022)
2.2.2 Global Anti-Parkinson Drugs Revenue and Market Share by Application (2017-2022)
2.3 Global Anti-Parkinson Drugs (Volume and Value) by Regions
2.3.1 Global Anti-Parkinson Drugs Consumption and Market Share by Regions (2017-2022)
2.3.2 Global Anti-Parkinson Drugs Revenue and Market Share by Regions (2017-2022)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2017-2022 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2017-2022 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2017-2022 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Anti-Parkinson Drugs Sales, Consumption, Export, Import by Regions (2017-2022)
4.1 Global Anti-Parkinson Drugs Consumption by Regions (2017-2022)
4.2 North America Anti-Parkinson Drugs Sales, Consumption, Export, Import (2017-2022)
4.3 East Asia Anti-Parkinson Drugs Sales, Consumption, Export, Import (2017-2022)
4.4 Europe Anti-Parkinson Drugs Sales, Consumption, Export, Import (2017-2022)
4.5 South Asia Anti-Parkinson Drugs Sales, Consumption, Export, Import (2017-2022)
4.6 Southeast Asia Anti-Parkinson Drugs Sales, Consumption, Export, Import (2017-2022)
4.7 Middle East Anti-Parkinson Drugs Sales, Consumption, Export, Import (2017-2022)
4.8 Africa Anti-Parkinson Drugs Sales, Consumption, Export, Import (2017-2022)
4.9 Oceania Anti-Parkinson Drugs Sales, Consumption, Export, Import (2017-2022)
4.10 South America Anti-Parkinson Drugs Sales, Consumption, Export, Import (2017-2022)
Chapter 5 North America Anti-Parkinson Drugs Market Analysis
5.1 North America Anti-Parkinson Drugs Consumption and Value Analysis
5.1.1 North America Anti-Parkinson Drugs Market Under COVID-19
5.2 North America Anti-Parkinson Drugs Consumption Volume by Types
5.3 North America Anti-Parkinson Drugs Consumption Structure by Application
5.4 North America Anti-Parkinson Drugs Consumption by Top Countries
5.4.1 United States Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
5.4.2 Canada Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
5.4.3 Mexico Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
Chapter 6 East Asia Anti-Parkinson Drugs Market Analysis
6.1 East Asia Anti-Parkinson Drugs Consumption and Value Analysis
6.1.1 East Asia Anti-Parkinson Drugs Market Under COVID-19
6.2 East Asia Anti-Parkinson Drugs Consumption Volume by Types
6.3 East Asia Anti-Parkinson Drugs Consumption Structure by Application
6.4 East Asia Anti-Parkinson Drugs Consumption by Top Countries
6.4.1 China Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
6.4.2 Japan Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
6.4.3 South Korea Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
Chapter 7 Europe Anti-Parkinson Drugs Market Analysis
7.1 Europe Anti-Parkinson Drugs Consumption and Value Analysis
7.1.1 Europe Anti-Parkinson Drugs Market Under COVID-19
7.2 Europe Anti-Parkinson Drugs Consumption Volume by Types
7.3 Europe Anti-Parkinson Drugs Consumption Structure by Application
7.4 Europe Anti-Parkinson Drugs Consumption by Top Countries
7.4.1 Germany Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
7.4.2 UK Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
7.4.3 France Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
7.4.4 Italy Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
7.4.5 Russia Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
7.4.6 Spain Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
7.4.7 Netherlands Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
7.4.8 Switzerland Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
7.4.9 Poland Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
Chapter 8 South Asia Anti-Parkinson Drugs Market Analysis
8.1 South Asia Anti-Parkinson Drugs Consumption and Value Analysis
8.1.1 South Asia Anti-Parkinson Drugs Market Under COVID-19
8.2 South Asia Anti-Parkinson Drugs Consumption Volume by Types
8.3 South Asia Anti-Parkinson Drugs Consumption Structure by Application
8.4 South Asia Anti-Parkinson Drugs Consumption by Top Countries
8.4.1 India Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
8.4.2 Pakistan Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
8.4.3 Bangladesh Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
Chapter 9 Southeast Asia Anti-Parkinson Drugs Market Analysis
9.1 Southeast Asia Anti-Parkinson Drugs Consumption and Value Analysis
9.1.1 Southeast Asia Anti-Parkinson Drugs Market Under COVID-19
9.2 Southeast Asia Anti-Parkinson Drugs Consumption Volume by Types
9.3 Southeast Asia Anti-Parkinson Drugs Consumption Structure by Application
9.4 Southeast Asia Anti-Parkinson Drugs Consumption by Top Countries
9.4.1 Indonesia Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
9.4.2 Thailand Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
9.4.3 Singapore Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
9.4.4 Malaysia Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
9.4.5 Philippines Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
9.4.6 Vietnam Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
9.4.7 Myanmar Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
Chapter 10 Middle East Anti-Parkinson Drugs Market Analysis
10.1 Middle East Anti-Parkinson Drugs Consumption and Value Analysis
10.1.1 Middle East Anti-Parkinson Drugs Market Under COVID-19
10.2 Middle East Anti-Parkinson Drugs Consumption Volume by Types
10.3 Middle East Anti-Parkinson Drugs Consumption Structure by Application
10.4 Middle East Anti-Parkinson Drugs Consumption by Top Countries
10.4.1 Turkey Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
10.4.2 Saudi Arabia Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
10.4.3 Iran Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
10.4.4 United Arab Emirates Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
10.4.5 Israel Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
10.4.6 Iraq Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
10.4.7 Qatar Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
10.4.8 Kuwait Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
10.4.9 Oman Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
Chapter 11 Africa Anti-Parkinson Drugs Market Analysis
11.1 Africa Anti-Parkinson Drugs Consumption and Value Analysis
11.1.1 Africa Anti-Parkinson Drugs Market Under COVID-19
11.2 Africa Anti-Parkinson Drugs Consumption Volume by Types
11.3 Africa Anti-Parkinson Drugs Consumption Structure by Application
11.4 Africa Anti-Parkinson Drugs Consumption by Top Countries
11.4.1 Nigeria Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
11.4.2 South Africa Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
11.4.3 Egypt Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
11.4.4 Algeria Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
11.4.5 Morocco Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
Chapter 12 Oceania Anti-Parkinson Drugs Market Analysis
12.1 Oceania Anti-Parkinson Drugs Consumption and Value Analysis
12.2 Oceania Anti-Parkinson Drugs Consumption Volume by Types
12.3 Oceania Anti-Parkinson Drugs Consumption Structure by Application
12.4 Oceania Anti-Parkinson Drugs Consumption by Top Countries
12.4.1 Australia Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
12.4.2 New Zealand Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
Chapter 13 South America Anti-Parkinson Drugs Market Analysis
13.1 South America Anti-Parkinson Drugs Consumption and Value Analysis
13.1.1 South America Anti-Parkinson Drugs Market Under COVID-19
13.2 South America Anti-Parkinson Drugs Consumption Volume by Types
13.3 South America Anti-Parkinson Drugs Consumption Structure by Application
13.4 South America Anti-Parkinson Drugs Consumption Volume by Major Countries
13.4.1 Brazil Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
13.4.2 Argentina Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
13.4.3 Columbia Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
13.4.4 Chile Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
13.4.5 Venezuela Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
13.4.6 Peru Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
13.4.7 Puerto Rico Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
13.4.8 Ecuador Anti-Parkinson Drugs Consumption Volume from 2017 to 2022
Chapter 14 Company Profiles and Key Figures in Anti-Parkinson Drugs Business
14.1 AbbVie
14.1.1 AbbVie Company Profile
14.1.2 AbbVie Anti-Parkinson Drugs Product Specification
14.1.3 AbbVie Anti-Parkinson Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.2 Hoffmann-La Roche
14.2.1 Hoffmann-La Roche Company Profile
14.2.2 Hoffmann-La Roche Anti-Parkinson Drugs Product Specification
14.2.3 Hoffmann-La Roche Anti-Parkinson Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.3 Novartis
14.3.1 Novartis Company Profile
14.3.2 Novartis Anti-Parkinson Drugs Product Specification
14.3.3 Novartis Anti-Parkinson Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.4 Mylan Laboratories
14.4.1 Mylan Laboratories Company Profile
14.4.2 Mylan Laboratories Anti-Parkinson Drugs Product Specification
14.4.3 Mylan Laboratories Anti-Parkinson Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.5 Pfizer, Inc.
14.5.1 Pfizer, Inc. Company Profile
14.5.2 Pfizer, Inc. Anti-Parkinson Drugs Product Specification
14.5.3 Pfizer, Inc. Anti-Parkinson Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.6 Valeant Pharmaceuticals
14.6.1 Valeant Pharmaceuticals Company Profile
14.6.2 Valeant Pharmaceuticals Anti-Parkinson Drugs Product Specification
14.6.3 Valeant Pharmaceuticals Anti-Parkinson Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.7 Orion Pharma
14.7.1 Orion Pharma Company Profile
14.7.2 Orion Pharma Anti-Parkinson Drugs Product Specification
14.7.3 Orion Pharma Anti-Parkinson Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.8 Zambon Pharmaceuticals
14.8.1 Zambon Pharmaceuticals Company Profile
14.8.2 Zambon Pharmaceuticals Anti-Parkinson Drugs Product Specification
14.8.3 Zambon Pharmaceuticals Anti-Parkinson Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.9 GlaxoSmithKline
14.9.1 GlaxoSmithKline Company Profile
14.9.2 GlaxoSmithKline Anti-Parkinson Drugs Product Specification
14.9.3 GlaxoSmithKline Anti-Parkinson Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.10 Merck & Co.
14.10.1 Merck & Co. Company Profile
14.10.2 Merck & Co. Anti-Parkinson Drugs Product Specification
14.10.3 Merck & Co. Anti-Parkinson Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.11 UCB
14.11.1 UCB Company Profile
14.11.2 UCB Anti-Parkinson Drugs Product Specification
14.11.3 UCB Anti-Parkinson Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.12 ACADIA Pharmaceuticals Inc.
14.12.1 ACADIA Pharmaceuticals Inc. Company Profile
14.12.2 ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Product Specification
14.12.3 ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.13 Teva Pharmaceutical Industries Ltd.
14.13.1 Teva Pharmaceutical Industries Ltd. Company Profile
14.13.2 Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Product Specification
14.13.3 Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.14 Vertical Pharmaceuticals, LLC
14.14.1 Vertical Pharmaceuticals, LLC Company Profile
14.14.2 Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Product Specification
14.14.3 Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
Chapter 15 Global Anti-Parkinson Drugs Market Forecast (2023-2028)
15.1 Global Anti-Parkinson Drugs Consumption Volume, Revenue and Price Forecast (2023-2028)
15.1.1 Global Anti-Parkinson Drugs Consumption Volume and Growth Rate Forecast (2023-2028)
15.1.2 Global Anti-Parkinson Drugs Value and Growth Rate Forecast (2023-2028)
15.2 Global Anti-Parkinson Drugs Consumption Volume, Value and Growth Rate Forecast by Region (2023-2028)
15.2.1 Global Anti-Parkinson Drugs Consumption Volume and Growth Rate Forecast by Regions (2023-2028)
15.2.2 Global Anti-Parkinson Drugs Value and Growth Rate Forecast by Regions (2023-2028)
15.2.3 North America Anti-Parkinson Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.4 East Asia Anti-Parkinson Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.5 Europe Anti-Parkinson Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.6 South Asia Anti-Parkinson Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.7 Southeast Asia Anti-Parkinson Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.8 Middle East Anti-Parkinson Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.9 Africa Anti-Parkinson Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.10 Oceania Anti-Parkinson Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.11 South America Anti-Parkinson Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.3 Global Anti-Parkinson Drugs Consumption Volume, Revenue and Price Forecast by Type (2023-2028)
15.3.1 Global Anti-Parkinson Drugs Consumption Forecast by Type (2023-2028)
15.3.2 Global Anti-Parkinson Drugs Revenue Forecast by Type (2023-2028)
15.3.3 Global Anti-Parkinson Drugs Price Forecast by Type (2023-2028)
15.4 Global Anti-Parkinson Drugs Consumption Volume Forecast by Application (2023-2028)
15.5 Anti-Parkinson Drugs Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology
